Beckman Coulter acquires nucleic acid technology firm:
This article was originally published in Clinica
Beckman Coulter has agreed to pay $100m, plus up to $40m in contingent payments until 2007, to acquire Agencourt Bioscience, a specialist in technology for the isolation and purification of RNA and DNA that reported sales of around $27m in 2004. Beckman Coulter says it will use Beverly, Massachusetts-based Agencourt's solid phase reversible immobilisation technology in its automated sample preparation systems for molecular testing and biomedical research. The acquired business will become a centre of excellence for nucleic acid science within Beckman Coulter's biomedical research division.